Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma

Blood Cancer J. 2020 Jan 27;10(1):9. doi: 10.1038/s41408-020-0276-7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Humans
  • Lymphoma, T-Cell / drug therapy*
  • Male
  • Middle Aged
  • Remission Induction / methods*